IBM Ventures participated in a $20m round for the neurological disease diagnostics technology spinout of Tel Aviv University.
Variantyx, a US-based developer of hereditary disease testing technology spun out of Tel Aviv University, received $20m yesterday in a series C round featuring IBM Ventures, the corporate venturing subsidiary of computing technology producer IBM.
GHS Fund, a joint venture between Quark Venture and GF Securities, led the round, which included Pitango Venture Capital, New Era Capital Partners and 20/20 HealthCare Partners.
Founded in 2014, Variantyx has developed genome sequencing technology used to test for rare inherited and…
